More than 20 industry leaders from companies supplying the UK’s National Health Service (NHS) with essential medicines warn that plans to change the Statutory Scheme for branded medicines are unworkable.
If implemented, the industry claims that the measures will reduce patient access to medicines, harm clinical research, and undermine investment in UK life sciences.
A government consultation proposing changes to the Statutory Scheme for branded medicines - replacing the soon-to-expire voluntary scheme for branded medicines pricing and access (VPAS) - has prompted the criticism.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze